Reported Q: Q4 2024 Rev YoY: +368.0% EPS YoY: +46.4% Move: -4.41%
Vaxart Inc
VXRT
$0.650 -4.41%
Exchange NASDAQ Sector Healthcare Industry Biotechnology
Q4 2024
Published: Mar 20, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for VXRT

Reported

Report Date

Mar 20, 2025

Quarter Q4 2024

Revenue

15.19M

YoY: +368.0%

EPS

-0.01

YoY: +46.4%

Market Move

-4.41%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $15.19M up 368% year-over-year
  • EPS of $-0.01 increased by 46.4% from previous year
  • Gross margin of 92.8%
  • Net income of -11.99M
  • "In January, an independent data safety monitoring board recommended the study to proceed without modifications based on initial safety assessment of the 30-day data." - Steven Lo
VXRT
Company VXRT

Swipe to view all report sections

Executive Summary

Vaxart posted a material revenue uptick in QQ4 2024 to $15.19 million, primarily driven by BARDA-related contracts and non-cash royalty revenue from Inavir in Japan, delivering a gross profit of $15.19 million and a gross margin of approximately 92.76%. Despite this top-line strength, the company remains unprofitable at the operating and net levels, reporting an operating loss of $11.49 million and a net loss of $11.99 million for the quarter, with a negative earnings per share of $0.0059. YoY revenue growth of 367.95% and gross profit growth of 642.54% reflect the government-funded revenue mix, while QoQ gains underscore the expanding, but still early-stage, revenue base. Cash and investments totaled about $51.7 million at year-end, with cash at end of period around $25.2 million; combined with a runway into Q4 2025, the liquidity position supports ongoing pipeline work and strategic reviews, albeit with meaningful near-term tailwinds and risks.

Management remains focused on extending the cash runway through partnerships and non-dilutive funding while continuing to advance multiple vaccine programs on its mucosal oral-vaccine platform. The BARDA stop-work order related to the 10,000-participant portion of the COVID-19 program introduces near-term uncertainty and cost containment pressures, including a workforce reduction in early 2025. The Norovirus program remains a meaningful growth vector, with a Phase 1 trial for second-generation constructs initiated and data publications in Science Translational Medicine reinforcing immunogenicity and cross-reactivity. Mid-2025 top-line Norovirus data are anticipated, which could serve as meaningful catalysts if safety and immunogenicity signals translate into protection, while regulatory and competitive dynamics in the broader norovirus space remain a critical risk.

Overall: QQ4 2024 demonstrates a revenue inflection driven by BARDA/royalty streams but underscored by the volatility of government-backed programs and the ongoing need to secure non-dilutive funding and strategic partnerships to sustain longer-term clinical development and manufacturing capabilities.

Key Performance Indicators

Revenue
Increasing
15.19M
QoQ: 207.82% | YoY: 367.95%
Gross Profit
Increasing
15.19M
92.76% margin
QoQ: 207.82% | YoY: 642.54%
Operating Income
Increasing
-11.49M
QoQ: 20.61% | YoY: 32.00%
Net Income
Increasing
-11.99M
QoQ: 14.88% | YoY: 31.02%
EPS
Increasing
-0.01
QoQ: 4.68% | YoY: 46.36%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2025 20.88 -0.07 +857.2% View
Q4 2024 15.19 -0.01 +368.0% View
Q3 2024 4.93 -0.01 +1.0% View
Q2 2024 6.40 -0.01 +371.4% View
Q1 2024 2.18 -0.01 +684.5% View